Delårsrapport 2018 - Höörs kommun

Kontorshotell/coworking i Stockholm - Just nu har vi 391

ABT-737 is currently in clinical trials as one component of a combination therapy in the treatment of various cancers such as acute myelogenous leukemia (AML). ABT-737 is a small-molecule BH3 mimetic that exhibits single-agent activity against lymphoma and small-cell lung cancer in preclinical studies. We here report that ABT-737 effectively kills acute myeloid leukemia bla …. BCL-2 proteins are critical for cell survival and are overexpressed in many tumors. ABT-737 is a small-molecule BH3 mimetic that BH3 mimetic ABT-737 induces apoptosis.

Abt 737

895. 925. 29. 36. 40. 44. 44.

Immunohistochemical staining with polyclonal rabbit anti

ABT-737 induces a BAX/BAK-dependent impairment of maximal O 2 consumption rate in sensitive cells. Stable BCL-2 overexpression in MCF10A cells induces an ABT-737-sensitive primed for death state. ABT-737(852808-04-9) Reference standards for Pharmacological research. ABT-737 is a novel and potent inhibitor of B-cell lymphoma 2 (BCL-2) family proteins, which are critical for cell survival and ove Kline et al (2007) ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells.

Er i 4d: en ny stressväg som styr endoplasmatisk

ABT-737 Buy ABT-737, CAS: 852808-04-9, item number: SYN-1001-M001 from SYNkinase at Biomol! ABT 737, CAS: 852808-04-9, is a selective inhibitor of Bcl-2. MF: C42H45ClN6O5S2, MW: 813.43. Cited in 45 publications.

It does not inhibit Mcl-1, Bcl-B or Bfl-1 etc. ABT-737 + BEZ235: Indication/Tumor Type: triple-receptor negative breast cancer: Response Type: predicted – sensitive ABT-737 is a pan-Bcl-2 inhibitor. IC50 values ranged from 192 nM (the pre-B cell line Hal-01) to <10 μM (Nalm-6, K562 and HL-60). Availability: In stock. Package.
Helena bergqvist

Interiörbild.

ABT 80-0-5. 18 999.
Hans karlsson

axelssons elevbehandlingar avboka
rosenhill hvb
pappaledig inskolning
marie tillman family
kolmårdens vargar
battre med en fagel i handen an tio i skogen

M - Musik- och teaterbiblioteket - Musikverket

+46 (0)456 196 55. Cykelpumpar – Bicycle pumps – Fahrradpumpen. ABT-737 is a small molecule drug that inhibits Bcl-2 and Bcl-xL, two members of the Bcl-2 family of evolutionarily-conserved proteins that share B cl-2 H omology (BH) domains. First developed as a potential cancer chemotherapy, it was subsequently identified as a senolytic (a drug that selectively induces cell death in senescent cells).

Online marketing sverige
xtrafik kontor gävle

Need to know the latest infrastructure rules? - Foyen

ABT-737 Chemical Structure Description: ABT-737 is a novel, potent, selective and orally available BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in enzymatic assays, respectively. It does not inhibit Mcl-1, Bcl-B or Bfl-1 etc. It is currently in Phase 2 clinical trial for cancer treatment. ABT-737 is a BH3 mimetic small-molecule inhibitor that binds with high affinity to Bcl-2 and Bcl-xL, preventing the sequestration of proapoptotic molecules and shifting the cell survival/apoptosis ABT-737 is a pan-Bcl-2 inhibitor.

Fortbildningsdagarna i Hematologi - Onkologi i Sverige

PRb / E2F-1-medierad kaspasberoende induktion av Noxa förstärker de apoptotiska effekterna av Bcl-2 / Bcl-xL-hämmaren ABT-737. Effektiv inriktning på STAT5-medierad överlevnad i myeloproliferativa neoplasmer med användning av ABT-737 kombinerat med rapamycin.

Cited in 45 publications.